Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cognetivity Neurosciences Ltd C.CGN

Alternate Symbol(s):  CGNSF

Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical and commercial environments and other neurological conditions. The Company’s CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. It is also focused on developing the ICA for home use, for the remote monitoring of patient’s progress under treatment regimens and for general home healthcare check-ups. CognICA is available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East. Its subsidiaries include Cognetivity Ltd. and Cognetivity FZ-LLC.


CSE:CGN - Post by User

Post by jolew32on Jun 13, 2023 10:07am
86 Views
Post# 35493450

Clairvo (US$28B Market Cap) = Big $$$ for CGN

Clairvo (US$28B Market Cap) = Big $$$ for CGN"Together, they aim to integrate CognICA into Clairvo's existing AI portfolio of health and wellness products, providing innovative cognitive monitoring capabilities to the Japanese population."

Mr. Riichi Yamada, President and CEO of Clairvo Technologies, added, "We are thrilled to join forces with Cognetivity Neurosciences, a leader in cognitive assessment technology. This collaboration aligns perfectly with our commitment to introducing innovative AI solutions that improve healthcare outcomes. By incorporating Cognetivity's cutting-edge cognitive assessment platform into our offerings, we aim to provide healthcare professionals in Japan with a powerful tool to enhance cognitive health management and support early interventions."
<< Previous
Bullboard Posts
Next >>